85 related articles for article (PubMed ID: 32064165)
1. Conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between EGFR and MEK or CDK4/6 inhibitors.
Wang Y; Liao H; Zheng T; Wang J; Guo D; Lu Z; Li Z; Chen Y; Shen L; Zhang Y; Gao J
Am J Cancer Res; 2020; 10(1):249-262. PubMed ID: 32064165
[TBL] [Abstract][Full Text] [Related]
2. Culture and application of conditionally reprogrammed primary tumor cells.
Zhong M; Fu L
Gastroenterol Rep (Oxf); 2020 Jun; 8(3):224-233. PubMed ID: 32665854
[TBL] [Abstract][Full Text] [Related]
3. Conditional Reprogramming Modeling of Bladder Cancer for Clinical Translation.
Daneshdoust D; Yin M; Luo M; Sundi D; Dang Y; Lee C; Li J; Liu X
Cells; 2023 Jun; 12(13):. PubMed ID: 37443748
[TBL] [Abstract][Full Text] [Related]
4. Unlocking Translational Potential: Conditionally Reprogrammed Cells in Advancing Breast Cancer Research.
Daneshdoust D; Luo M; Li Z; Mo X; Alothman S; Kallakury B; Schlegel R; Zhang J; Guo D; Furth PA; Liu X; Li J
Cells; 2023 Sep; 12(19):. PubMed ID: 37830602
[TBL] [Abstract][Full Text] [Related]
5. Conditionally Reprogrammed Cells and Robotic High-Throughput Screening for Precision Cancer Therapy.
Alkhilaiwi F
Front Oncol; 2021; 11():761986. PubMed ID: 34737964
[TBL] [Abstract][Full Text] [Related]
6. Conditional reprogramming: Modeling urological cancer and translation to clinics.
Liu W; Ju L; Cheng S; Wang G; Qian K; Liu X; Xiao Y; Wang X
Clin Transl Med; 2020 Jun; 10(2):e95. PubMed ID: 32508060
[TBL] [Abstract][Full Text] [Related]
7. Rapid screening for individualized chemotherapy optimization of colorectal cancer: A novel conditional reprogramming technology-based functional diagnostic assay.
Li Y; Guo D; Zhang Y; Wang L; Sun T; Li Z; Zhang X; Wang S; Chen Y; Wu A
Transl Oncol; 2021 Jan; 14(1):100935. PubMed ID: 33190042
[TBL] [Abstract][Full Text] [Related]
8. Use of Radiomics to Predict Response to Immunotherapy of Malignant Tumors of the Digestive System.
Ji Z; Cui Y; Peng Z; Gong J; Zhu HT; Zhang X; Li J; Lu M; Lu Z; Shen L; Sun YS
Med Sci Monit; 2020 Oct; 26():e924671. PubMed ID: 33077705
[TBL] [Abstract][Full Text] [Related]
9. The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer.
Peng Z; Cheng S; Kou Y; Wang Z; Jin R; Hu H; Zhang X; Gong JF; Li J; Lu M; Wang X; Zhou J; Lu Z; Zhang Q; Tzeng DTW; Bi D; Tan Y; Shen L
Cancer Immunol Res; 2020 Oct; 8(10):1251-1261. PubMed ID: 32855157
[TBL] [Abstract][Full Text] [Related]
10. Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer.
Lu Z; Chen H; Li S; Gong J; Li J; Zou J; Wu L; Yu J; Han W; Sun H; Jiao X; Zhang X; Peng Z; Lu M; Wang Z; Zhang H; Shen L
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32792358
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives.
Zhang Z; Xie T; Zhang X; Qi C; Shen L; Peng Z
Chin J Cancer Res; 2020 Jun; 32(3):287-302. PubMed ID: 32694895
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic therapy inhibits metastases by disrupting premetastatic niches.
Lu Z; Zou J; Li S; Topper MJ; Tao Y; Zhang H; Jiao X; Xie W; Kong X; Vaz M; Li H; Cai Y; Xia L; Huang P; Rodgers K; Lee B; Riemer JB; Day CP; Yen RC; Cui Y; Wang Y; Wang Y; Zhang W; Easwaran H; Hulbert A; Kim K; Juergens RA; Yang SC; Battafarano RJ; Bush EL; Broderick SR; Cattaneo SM; Brahmer JR; Rudin CM; Wrangle J; Mei Y; Kim YJ; Zhang B; Wang KK; Forde PM; Margolick JB; Nelkin BD; Zahnow CA; Pardoll DM; Housseau F; Baylin SB; Shen L; Brock MV
Nature; 2020 Mar; 579(7798):284-290. PubMed ID: 32103175
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial.
Lu M; Zhang P; Zhang Y; Li Z; Gong J; Li J; Li J; Li Y; Zhang X; Lu Z; Wang X; Zhou J; Peng Z; Wang W; Feng H; Wu H; Yao S; Shen L
Clin Cancer Res; 2020 May; 26(10):2337-2345. PubMed ID: 32086343
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictive efficacy of C-reactive protein for diagnosing infectious complications after gastric surgery.
Shi J; Wu Z; Wang Q; Zhang Y; Shan F; Hou S; Ying X; Huangfu L; Li Z; Ji J
Therap Adv Gastroenterol; 2020; 13():1756284820936542. PubMed ID: 32670413
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived xenograft model in colorectal cancer basic and translational research.
Liu X; Xin Z; Wang K
Animal Model Exp Med; 2023 Feb; 6(1):26-40. PubMed ID: 36543756
[TBL] [Abstract][Full Text] [Related]
16. Functional Drug Screening in the Era of Precision Medicine.
Napoli GC; Figg WD; Chau CH
Front Med (Lausanne); 2022; 9():912641. PubMed ID: 35879922
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-Dependent Kinase 4/6 Inhibitors: A Potential Breakthrough Therapy for Malignancies of Gastrointestinal Tract.
Zeng F; Zhou Y; Khowtanapanich T; Saengboonmee C
In Vivo; 2022; 36(4):1580-1590. PubMed ID: 35738597
[TBL] [Abstract][Full Text] [Related]
18. Application Research of Individualized Conditional Reprogramming System to Guide Treatment of Gastric Cancer.
Zhao W; Liu K; Sun Z; Wang L; Liu B; Liu L; Qu X; Cao Z; Sun J; Chai J
Front Oncol; 2021; 11():709511. PubMed ID: 34336697
[TBL] [Abstract][Full Text] [Related]
19. Conditional Cell Reprogramming in Modeling Digestive System Diseases.
Zhao R; Li R; An T; Liu X
Front Cell Dev Biol; 2021; 9():669756. PubMed ID: 34150763
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck.
van Caloen G; Schmitz S; van Marcke C; Caignet X; Mendola A; Pyr Dit Ruys S; Roger PP; Vertommen D; Machiels JP
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
